首页> 美国卫生研究院文献>British Heart Journal >Changes in membrane glycoproteins of circulating platelets after coronary stent implantation.
【2h】

Changes in membrane glycoproteins of circulating platelets after coronary stent implantation.

机译:冠状动脉支架植入术后循环血小板膜糖蛋白的变化。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

OBJECTIVES: To evaluate platelet function in patients with coronary stents. DESIGN: A non-randomised control trial in 30 patients who had immediate implantation of Palmaz-Schatz coronary stents because of a suboptimal angioplasty result. All patients received a standardised anticoagulation regimen including intravenous heparin (activated partial thromboplastin time (APTT) 80 to 120 s), oral vitamin K antagonist (target international normalised ratio (INR) of 3.5), and 100 mg aspirin twice daily. Platelet surface expression of glycoprotein IIb-IIIa, activated fibrinogen receptor, and P-selectin as well as binding of von Willebrand factor and fibrinogen were determined by flow cytometry in peripheral venous blood samples collected before the intervention and then daily for 4 days after it. The results were compared with those in 30 patients undergoing elective coronary balloon angioplasty. SETTING: University hospital. RESULTS: After coronary stenting surface expression of the activated fibrinogen receptor significantly increased, peaking at day 2 (P < 0.001). Similar results were found for von Willebrand factor binding and P-selectin surface expression, with a maximum at day 2 to 4 after stenting (von Willebrand factor, P < 0.001; P-selectin, P < 0.001). The changes in platelet membrane glycoproteins coincided with a significant drop in peripheral platelet count after stent placement (P < 0.01). No significant change in fibrinogen receptor activity, von Willebrand factor binding, P-selectin surface expression, or platelet count was seen in the control group. CONCLUSIONS: The present study shows that current anticoagulation treatment is inefficient in suppressing platelet activation in patients with coronary stents and, therefore, might not be the best treatment for reducing the incidence of subacute stent thrombosis.
机译:目的:评估冠状动脉支架患者的血小板功能。设计:一项非随机对照试验,针对30例因血管成形术结果欠佳而立即植入Palmaz-Schatz冠状动脉支架的患者。所有患者均接受标准抗凝方案,包括静脉肝素(活化部分凝血活酶时间(APTT)80至120 s),口服维生素K拮抗剂(目标国际标准化比率(INR)为3.5)和每天两次100 mg阿司匹林。通过流式细胞术在干预前收集的外周静脉血样品中测定糖蛋白IIb-IIIa,活化的纤维蛋白原受体和P-选择素的血小板表面表达以及von Willebrand因子和纤维蛋白原的结合,然后每天进行4天。将结果与30例行择期冠状动脉球囊成形术的患者进行比较。地点:大学医院。结果:冠状动脉支架置入后,活化纤维蛋白原受体的表面表达显着增加,在第2天达到峰值(P <0.001)。发现von Willebrand因子结合和P-选择素表面表达的结果相似,在支架置入后第2至4天达到最大值(von Willebrand因子,P <0.001; P-选择素,P <0.001)。支架置入后血小板膜糖蛋白的变化与外周血小板计数的显着下降相吻合(P <0.01)。在对照组中,未发现纤维蛋白原受体活性,von Willebrand因子结合,P-选择蛋白表面表达或血小板计数有显着变化。结论:本研究表明,目前的抗凝治疗不能有效抑制冠状动脉支架患者的血小板活化,因此可能不是降低亚急性支架血栓形成发生率的最佳治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号